Literature DB >> 19372222

The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.

Hans C A Raaijmakers1, Judith E Versteegh, Joost C M Uitdehaag.   

Abstract

Here we describe the 1.95 A structure of the clinically used antiprogestin RU486 (mifepristone) in complex with the progesterone receptor (PR). The structure was obtained by taking a crystal of the PR ligand binding domain containing the agonist norethindrone and soaking it in a solution containing the antagonist RU486 for extended times. Clear ligand exchange could be observed in one copy of the PR ligand binding domain dimer in the crystal. RU486 binds while PR is in an agonistic conformation without displacing helix 12. Although this is probably because of the constraints of the crystal lattice, it demonstrates that helix 12 displacement is not a prerequisite for RU486 binding. Interestingly, B-factor analysis clearly shows that helix 12 becomes more flexible after RU486 binding, suggesting that RU486, being a model antagonist, does not induce one fixed conformation of helix 12 but changes its positional equilibrium. This conclusion is confirmed by comparing the structures of RU486 bound to PR and RU486 bound to the glucocorticoid receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372222      PMCID: PMC2740583          DOI: 10.1074/jbc.M109.007872

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  RU486 (mifepristone): mechanisms of action and clinical uses.

Authors:  F Cadepond; A Ulmann; E E Baulieu
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

2.  Atomic structure of progesterone complexed with its receptor.

Authors:  S P Williams; P B Sigler
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

3.  Human progesterone receptor A and B isoforms in CHO cells. I. Stable transfection of receptor and receptor-responsive reporter genes: transcription modulation by (anti)progestagens.

Authors:  R Dijkema; W G Schoonen; R Teuwen; E van der Struik; R J de Ries; B A van der Kar; W Olijve
Journal:  J Steroid Biochem Mol Biol       Date:  1998-02       Impact factor: 4.292

4.  The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor.

Authors:  E Vegeto; G F Allan; W T Schrader; M J Tsai; D P McDonnell; B W O'Malley
Journal:  Cell       Date:  1992-05-15       Impact factor: 41.582

5.  Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists.

Authors:  David G Jones; Xi Liang; Eugene L Stewart; Robert A Noe; Lara S Kallander; Kevin P Madauss; Shawn P Williams; Scott K Thompson; David W Gray; William J Hoekstra
Journal:  Bioorg Med Chem Lett       Date:  2005-07-01       Impact factor: 2.823

6.  Determination of conformational changes in the progesterone receptor using ELISA-like assays.

Authors:  Mark A Pullen; Nicholas Laping; Richard Edwards; Jeffrey Bray
Journal:  Steroids       Date:  2006-06-19       Impact factor: 2.668

7.  A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.

Authors:  Kevin P Madauss; Eugene T Grygielko; Su-Jun Deng; Anthony C Sulpizio; Thomas B Stanley; Charlene Wu; Steve A Short; Scott K Thompson; Eugene L Stewart; Nicholas J Laping; Shawn P Williams; Jeffrey D Bray
Journal:  Mol Endocrinol       Date:  2007-03-13

8.  Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones.

Authors:  W G Schoonen; G Deckers; M E de Gooijer; R de Ries; G Mathijssen-Mommers; H Hamersma; H J Kloosterboer
Journal:  J Steroid Biochem Mol Biol       Date:  2000-10       Impact factor: 4.292

9.  A single amino acid that determines the sensitivity of progesterone receptors to RU486.

Authors:  B Benhamou; T Garcia; T Lerouge; A Vergezac; D Gofflo; C Bigogne; P Chambon; H Gronemeyer
Journal:  Science       Date:  1992-01-10       Impact factor: 47.728

10.  Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes.

Authors:  Kevin P Madauss; Su-Jun Deng; Robert J H Austin; Millard H Lambert; Iain McLay; John Pritchard; Steven A Short; Eugene L Stewart; Ian J Uings; Shawn P Williams
Journal:  J Med Chem       Date:  2004-06-17       Impact factor: 7.446

View more
  24 in total

1.  Differential responses of progesterone receptor membrane component-1 (Pgrmc1) and the classical progesterone receptor (Pgr) to 17β-estradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis.

Authors:  Namrata Bali; Jason M Arimoto; Nahoko Iwata; Sharon W Lin; Liqin Zhao; Roberta D Brinton; Todd E Morgan; Caleb E Finch
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

2.  X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Bert Kazemier; Rolien Bosch; Ross McGuire; Rita Azevedo; Hans Hamersma; Koen Dechering; Arthur Oubrie; Marcel van Duin; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 3.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

4.  Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.

Authors:  Scott J Lusher; Hans C A Raaijmakers; Diep Vu-Pham; Koen Dechering; Tsang Wai Lam; Angus R Brown; Niall M Hamilton; Olaf Nimz; Rolien Bosch; Ross McGuire; Arthur Oubrie; Jacob de Vlieg
Journal:  J Biol Chem       Date:  2011-08-17       Impact factor: 5.157

Review 5.  Progestin therapy to prevent preterm birth: History and effectiveness of current strategies and development of novel approaches.

Authors:  Sam A Mesiano; Gregory A Peters; Peyvand Amini; Rachel A Wilson; Gregory P Tochtrop; Focco van Den Akker
Journal:  Placenta       Date:  2019-01-28       Impact factor: 3.481

6.  Revealing a steroid receptor ligand as a unique PPARγ agonist.

Authors:  Shengchen Lin; Ying Han; Yuzhe Shi; Hui Rong; Songyang Zheng; Shikan Jin; Shu-Yong Lin; Sheng-Cai Lin; Yong Li
Journal:  Cell Res       Date:  2011-10-11       Impact factor: 25.617

7.  Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin.

Authors:  Steven K Nordeen; Betty J Bona; David N Jones; James R Lambert; Twila A Jackson
Journal:  Horm Cancer       Date:  2013-07-09       Impact factor: 3.869

Review 8.  Structural and functional analysis of domains of the progesterone receptor.

Authors:  Krista K Hill; Sarah C Roemer; Mair E A Churchill; Dean P Edwards
Journal:  Mol Cell Endocrinol       Date:  2011-07-22       Impact factor: 4.102

9.  Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

Authors:  Ioannis Zalachoras; René Houtman; Erika Atucha; Rene Devos; Ans M I Tijssen; Pu Hu; Peter M Lockey; Nicole A Datson; Joseph K Belanoff; Paul J Lucassen; Marian Joëls; E Ronald de Kloet; Benno Roozendaal; Hazel Hunt; Onno C Meijer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-23       Impact factor: 11.205

Review 10.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.